Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D04MXN
|
|||
Former ID |
DIB002218
|
|||
Drug Name |
CEP-32496
|
|||
Synonyms |
AB-024; B-RAF kinase inhibitors (melanoma), Ambit/Cephalon
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1/2 | [1], [2] | |
Company |
Teva pharmaceutical
|
|||
Structure |
![]() |
Download2D MOL |
||
Formula |
C24H22F3N5O5
|
|||
Canonical SMILES |
CC(C)(C1=CC(=NO1)NC(=O)NC2=CC(=CC=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(F)(F)F
|
|||
InChI |
1S/C24H22F3N5O5/c1-23(2,24(25,26)27)19-11-20(32-37-19)31-22(33)30-13-6-5-7-14(8-13)36-21-15-9-17(34-3)18(35-4)10-16(15)28-12-29-21/h5-12H,1-4H3,(H2,30,31,32,33)
|
|||
InChIKey |
DKNUPRMJNUQNHR-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 1188910-76-0
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7880). | |||
REF 2 | ClinicalTrials.gov (NCT01877811) CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2. U.S. National Institutes of Health. | |||
REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 4 | Clinical pipeline report, company report or official report of Ambit Biosciences. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.